Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer
- Conditions
- Breast Neoplasm
- Interventions
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2019-08-15
- Lead Sponsor
- Instituto Nacional de Cancer, Brazil
- Target Recruit Count
- 20
- Registration Number
- NCT03024580
- Locations
- 🇧🇷
Hospital do Cancer III, Rio de Janeiro, Brazil
GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer
- Conditions
- Advanced Estrogen Receptor Positive HER2- Breast Cancer
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 14
- Registration Number
- NCT02983604
- Locations
- 🇺🇸
Stanford Women's Cancer Center, Stanford, California, United States
🇺🇸Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States
🇺🇸Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane, Washington, United States
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
- Conditions
- Estrogen Receptor Positive Breast CancerHER-2 Positive Breast Cancer
- Interventions
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 496
- Registration Number
- NCT02947685
- Locations
- 🇺🇸
University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Hamdy A. Azim
- Target Recruit Count
- 160
- Registration Number
- NCT02917005
- Locations
- 🇿🇦
Wits Oncology center, Johannesburg, South Africa
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
- Conditions
- Breast CancerHormone Receptor Positive TumorHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Interventions
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 388
- Registration Number
- NCT02894398
- Locations
- 🇩🇪
Research Site, Wilhelmshaven, Germany
Palbociclib With Everolimus + Exemestane In BC
- Conditions
- Human Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor (HR)-Positive Breast Cancer
- Interventions
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2022-08-29
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 41
- Registration Number
- NCT02871791
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Taizhou EOC Pharma Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT02833155
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy Medical Sciences, Beijing, Beijing, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
- Conditions
- Breast CancerEstrogen Receptor Positive Breast Cancer
- Interventions
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT02820961
- Locations
- 🇺🇸
Sarah Cannon Research Institute HealthONE, Denver, Colorado, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 500
- Registration Number
- NCT02765373
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT02732119
- Locations
- 🇺🇸
Florida Cancer Specialists FL Cancer Specialists, Fort Myers, Florida, United States
🇺🇸St. Luke's Cancer Institute Regulatory, Kansas City, Missouri, United States
🇺🇸Research Medical Center HCA Midwest Division, Kansas City, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.